Apremilast, an oral phosphodiesterase-4 (PDE-4) inhibitor, is widely used in the treatment of inflammatory diseases such as psoriasis and psoriasis arthritis. However, its poor water solubility to formulate and evaluate a Nanoemulsion (NE) system for Apremilast to enhance its solubility, stability, and bioavailability. A Nanoemulsion was developed using a high energy emulsification method, with a combination of oil, surfactant, and co-surfactant carefully selected based on solubility studies and construction of pseudo-ternary phase diagrams. Various formulations were prepared and evaluated for droplet size, polydispersity index (PDI), zeta potential, and drug encapsulation efficiency. The optimized formulation exhibited a droplet size of below 600 nm, a low PDI, and a stable zeta potential, confirming its stability. According to this report, the Nanoemulsion based delivery system for Apremilast drug could offer significant clinical advantages, particularly in terms of improved pharmacokinetics and enhanced therapeutics outcomes, paving the way for more effective treatment of inflammatory diseases such as psoriasis and psoriatic arthritis. Further in vivo studies are recommended to confirm the observed benefits and to evaluate long term safety and efficacy.